UT Dots Inc. is a nanotechnology research and manufacturing company based at the University of Illinois Research Park at Champaign, Illinois. The company specializes in manufacturing high quality silver and gold nanoinks. Their current technology enables continuous production of nanoparticles of desired chemical nature and quality from aerosol.
Varian's scientific instruments and vacuum technologies, consumable supplies, and solutions are key tools in bio-molecular and academic research, pharmaceutical R&D and manufacturing, and industrial R&D and quality control.
Vascular Magnetics, Inc. is magnetically targeting drug-loaded biodegradable nanoparticles to develop Vascular Magnetic Intervention (VMI), a novel therapy for peripheral artery disease (PAD). PAD is a common chronic condition characterized by obstruction (stenosis) of the arteries in the legs.
The company is developing Drug-Coated Balloons (DCB) that are designed to be a more precise delivery vehicle and be the standard treatment of choice for vascular atherosclerosis as well as non-vascular applications.
Velocys, Inc. is commercializing revolutionary processing systems, including nanoscale ones, that provide energy companies with new synthetic fuels and chemical companies with substantial capital cost savings, improved product yields, and greater energy efficiencies.
Vendum Batteries Inc. is developing an innovative new cellulose-based power source that in the next few years could help revolutionize the powering of the automotive and aeronautical industries. This revolutionary battery is entirely biodegradable, as it is primarily composed of cellulose and uses none of the toxic elements used in traditional batteries, such as mercury, lead, chromium, or cadmium. Using cutting edge Carbon Nanotube Technology, this non toxic power source, will in the future be capable of providing higher power output, for longer periods of time, and because the batteries can be so small and light weight, it will be possible to revolutionize human implant technology such as pacemakers or cochlear implants.
VisiGen Biotechnologies, Inc. is developing a revolutionary approach for DNA sequencing that will enable rapid, inexpensive whole genome sequencing. The VisiGen® sequencing system will become an enabling platform technology for single-molecule genetic analysis.
WaferGen Biosystems, Inc. is a leader in the development, manufacture and commercialization of next-generation systems for gene expression, genotyping, stem cell research and cell biology for the life science and pharmaceutical industries.